CRISPR Therapeutics AG (CRSP) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving CRISPR Therapeutics AG (CRSP) right now is First-Mover Advantage in Commercial Gene Editing: Casgevy is the world's first approved CRISPR-based medicine, giving CRISPR Therapeutics a durable head start in manufacturing know-how, regulatory relationships, and patient community trust. Revenue (Full Year 2025, product only) is ~$3.5 million. If that keeps playing out, the setup is favourable; the risk to it is the commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. No one can predict where CRSP trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive CRISPR Therapeutics AG (CRSP) higher?
First-Mover Advantage in Commercial Gene Editing
Casgevy is the world's first approved CRISPR-based medicine, giving CRISPR Therapeutics a durable head start in manufacturing know-how, regulatory relationships, and patient community trust. No direct CRISPR competitor has yet reached commercial approval for the same indications. That first-mover status matters because gene therapy infrastructure, including certified treatment centers and payer contracting, takes years to build.
Casgevy's Long-Term Revenue Potential
Sickle cell disease affects an estimated 100,000 patients in the United States alone, and transfusion-dependent beta-thalassemia adds tens of thousands more globally. Analysts have modeled Casgevy's peak annual sales in the billions of dollars if reimbursement access broadens and the treatment process is simplified. Reimbursement agreements are expanding in multiple countries, and Vertex's global commercial infrastructure handles the rollout.
Diversified Pipeline with Blockbuster Potential
Beyond Casgevy, clinical-stage CAR-T programs CTX112 and CTX131 target B-cell malignancies and autoimmune diseases, with broad data updates anticipated in 2025 and 2026. In vivo cardiovascular candidates CTX310 and CTX320 target ANGPTL3 and LPA respectively, addressing large patient populations. The 2025 acquisition of CTX611, a long-acting siRNA therapy silencing Factor XI for thrombosis prevention, further widens the addressable market.
Strong Balance Sheet Providing Operational Runway
CRISPR Therapeutics closed 2025 with approximately $1.98 billion in liquidity, which management states is sufficient to fund operations for at least 24 months. That cash cushion means the company is unlikely to need emergency dilutive financing in the near term, giving the pipeline time to generate clinical data. A subsequent convertible notes offering in early 2026 supplemented the position further.
What could weigh on CRSP?
The commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. The expiration of CRISPR's cost-deferral agreement with Vertex drove collaboration expenses up roughly 77 percent year over year in 2025, contributing to a full-year operating loss of approximately $665 million, and the company must repay around $222 million in previously deferred costs before net cash flows from Casgevy accrue to CRSP shareholders. Competing gene-editing and cell-therapy platforms from Intellia Therapeutics, Beam Therapeutics, and large pharmaceutical companies pursuing in vivo approaches could erode CRSP's differentiation over time. The stock also carries high short interest, above 22 percent of shares outstanding as of recent data, reflecting meaningful institutional skepticism about the pace of the commercial ramp.
How to think about a CRSP forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the CRSP guide and whether CRSP is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the CRSP outlook
The bottom line: what is driving CRISPR Therapeutics AG (CRSP) is First-Mover Advantage in Commercial Gene Editing, with revenue (full year 2025, product only) at ~$3.5 million. If that keeps playing out the setup is favourable; the risk is the commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. No one can predict the price, so treat any CRSP forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around CRSP with Walnut
Use CRISPR Therapeutics AG as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for CRISPR Therapeutics AG (CRSP)?
+
No one can reliably predict where CRSP will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push CRISPR Therapeutics AG higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive CRSP higher?
+
The main growth drivers are First-Mover Advantage in Commercial Gene Editing; Casgevy's Long-Term Revenue Potential; Diversified Pipeline with Blockbuster Potential. Whether they play out is the real question, not a guaranteed path.
What are the risks to CRSP?
+
The commercial ramp of Casgevy has been far slower than early projections, with the therapy generating only approximately $3.5 million in revenue in all of 2025, down sharply from prior years that were boosted by one-time milestone payments. The expiration of CRISPR's cost-deferral agreement with Vertex drove collaboration expenses up roughly 77 percent year over year in 2025, contributing to a full-year operating loss of approximately $665 million, and the company must repay around $222 million in previously deferred costs before net cash flows from Casgevy accrue to CRSP shareholders. Competing gene-editing and cell-therapy platforms from Intellia Therapeutics, Beam Therapeutics, and large pharmaceutical companies pursuing in vivo approaches could erode CRSP's differentiation over time. The stock also carries high short interest, above 22 percent of shares outstanding as of recent data, reflecting meaningful institutional skepticism about the pace of the commercial ramp.
Will CRSP stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. CRISPR Therapeutics AG's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is CRSP a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the CRSP "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.